Dualyx

Biotech · Ghent, BE

Develops immune-modulation therapeutics targeting TNFR2 for autoimmune diseases

In the network

Shares the most investors with (number = shared investors):

Create a free EquityFlow account to see Dualyx's 1 funding round, 3 investors, 12 similar companies.